Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effets du volume des boissons, de la concentration en glycérol et de la concentration en sodium sur l'équilibre des liquides chez les hommes et les femmes d'Euhydrate en bonne santé au repos

16 septembre 2026 mis à jour par: PepsiCo Global R&D

The presence of certain ingredients such as sodium and glycerol can facilitate retention of the fluid consumed via renal water reabsorption. To maintain overall whole-body fluid balance, it is important that ingested fluid is retained in the body instead of losing it through urination.

The purpose of this study is to determine the effect of sodium and glycerol concentrations at various fluid intake volumes on fluid balance in healthy, euhydrated men and women.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Florida
      • Bradenton, Florida, États-Unis, 34210
        • IMG Academy/GSSI Bradenton Gatorade Sports Science Institute
      • St. Petersburg, Florida, États-Unis, 33705
        • GCP Research
    • New York
      • Valhalla, New York, États-Unis, 10595
        • Gatorade Sports Science Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 50 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Subject is male or female
  • If female, subject is not pregnant
  • Subject is 18-50 years of age, inclusive
  • Subject is at least recreationally active (engaged in light to moderate-intensity, intermittent, or steady-state exercise at least 3 days per week for at least 30 min at a time)
  • Subject does not smoke (or has quit for at least 6 months)
  • Subject is not taking medication that may interfere with the study (e.g., diuretics)
  • Subject has no health conditions that would interfere with the study (e.g. cardiovascular, renal, or metabolic diseases)
  • Subject is willing to avoid alcohol consumption 24 hours prior to visit(s)
  • Subject is willing to fast overnight (~8-12 hours)
  • Subject is willing to refrain from vigorous exercise for 24 hours
  • Subject is willing to eat the exact same food the day prior to each visit to the laboratory
  • Provision of written consent to participate

Exclusion Criteria:

  • Subject has participated in a clinical trial within the past 30 days
  • Subject has participated in any PepsiCo trial within past 6 months
  • Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk
  • Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo beverage

Base beverage, no electrolytes, no glycerol

9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose

Expérimental: Electrolyte solution without glycerol beverage 1

Higher electrolytes lower volume

4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Electrolyte solution without glycerol beverage 2

Lower electrolytes mid-volume

6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Electrolyte solution without glycerol beverage 3

Higher electrolytes higher volume

9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Electrolyte solution with glycerol beverage 1

Lower electrolytes, lower glycerol, lower volume

4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Electrolyte solution with glycerol beverage 2

Higher electrolytes, higher glycerol, lower volume

4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Electrolyte solution with glycerol beverage 3

Higher electrolytes, higher glycerol, higher volume

9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Base with glycerol beverage 1

No electrolytes, higher glycerol, lower volume

4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Base with glycerol beverage 2

No electrolytes, lower glycerol, mid-volume

6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Expérimental: Base with glycerol beverage 3

No electrolytes, higher glycerol, higher volume

9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Fluid balance
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

Calculated as change in body mass kg and %

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Urine mass
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

(g)

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes
Urine specific gravity
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

(au)

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes
Urine osmolality
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

(mosmol/kg)

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes
Whole blood hematocrit
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(%)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Whole blood hemoglobin concentration
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(g/dl)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum sodium concentration
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(mmol/L)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum potassium concentration
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(mmol/L)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum chloride concentration (mmol/L)
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(mmol/L)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum glucose concentration
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(mg/dl)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum glycerol concentration
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(mmol/L)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum copeptin concentration
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(pmol/L)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Serum osmolality
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes

(mosmol/kg)

Change from baseline (pre-beverage) to post-beverage Time 30, 90,150 and 210 minutes
Blood pressure
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

(systolic/diastolic) (mmHg)

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes
Heart rate
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

(bpm)

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes
Subjective measures of gastrointestinal discomfort and headache (VAS)
Délai: Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes

Rated on a 100 point scale from none to severe for headache, lightheaded, stomach upset, nausea, burping, stomach bloating, abdominal discomfort, stomach fullness, vomiting, diarrhea).

Change from baseline (pre-beverage) to post-beverage Time 30, 60, 90,120, 150,180 and 210 minutes
Menstrual categorization
Délai: Screening visit

Current status (e.g., contraception, regular periods or not, etc.)

Screening visit
Adverse Events
Délai: From Screening (Visit 1) through the fifth and final beverage testing day (Visit 6)

Documented changes in health and symptoms

From Screening (Visit 1) through the fifth and final beverage testing day (Visit 6)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Lindsay Baker, PhD, PepsiCo R&D/Gatorade and Sports Science Institute

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

18 juillet 2025

Achèvement primaire (Réel)

2 décembre 2025

Achèvement de l'étude (Réel)

2 décembre 2025

Dates d'inscription aux études

Première soumission

19 février 2025

Première soumission répondant aux critères de contrôle qualité

28 février 2025

Première publication (Réel)

3 mars 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • PEP-2420

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner